enoxacin has been researched along with Ewing Sarcoma in 2 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JA | 1 |
| Crawford, KA | 1 |
| Spada, PA | 1 |
| Martin, LR | 1 |
| Zhang, J | 1 |
| Wong, R | 1 |
| Reid, JM | 1 |
| Stewart, CF | 1 |
| Frank, TM | 1 |
| Liu, Q | 1 |
| Michalek, JE | 1 |
| Keller, C | 1 |
| Cornaz-Buros, S | 1 |
| Riggi, N | 1 |
| DeVito, C | 1 |
| Sarre, A | 1 |
| Letovanec, I | 1 |
| Provero, P | 1 |
| Stamenkovic, I | 1 |
2 other studies available for enoxacin and Ewing Sarcoma
| Article | Year |
|---|---|
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Animals; Benzamides; Disease Models, Animal; Enoxac | 2023 |
Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Bone Neoplasms; Cell Line, Tumor; Doxorubicin; Enoxacin; Glyco | 2014 |